Tamoxifen for the treatment of myeloproliferative neoplasms: a phase II clinical trial and exploratory analysis

<p>Current therapies for myeloproliferative neoplasms (MPNs) improve symptoms but have limited effect on tumor size. In preclinical studies, tamoxifen restored normal apoptosis in mutated hematopoietic stem/progenitor cells (HSPCs). TAMARIN Phase-II, multicenter, single-arm clinical trial asse...

Full description

Bibliographic Details
Main Authors:	Fang, Z, Corbizi Fattori, G, McKerrell, T, Boucher, RH, Jackson, A, Fletcher, RS, Forte, D, Martin, J-E, Fox, S, Roberts, J, Glover, R, Harris, E, Bridges, HR, Grassi, L, Rodriguez-Meira, A, Mead, AJ, Knapper, S, Ewing, J, Butt, NM, Jain, M, Francis, S, Clark, FJ, Coppell, J, McMullin, MF, Wadelin, F, Narayanan, S, Milojkovic, D, Drummond, MW, Sekhar, M, ElDaly, H, Hirst, J, Paramor, M, Baxter, EJ, Godfrey, AL, Harrison, CN, Méndez-Ferrer, S
Format:	Journal article
Language:	English
Published:	Springer Nature 2023

Tamoxifen for the treatment of myeloproliferative neoplasms: a phase II clinical trial and exploratory analysis

Similar Items